Sjögren's disease & overlap diseases
Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren’s disease
Primary result · Response rate, active treatment vs placebo, by cluster (pooled)Result — go to the resultResponse rate 61.5% vs 32.6%Authors' conclusion
Transcriptomic stratification of SjD patients revealed differential responses to HCQ-LEF and RTX.
Study context
- Population
- Sjögren's disease (SjD) patients from 3 RCTs: Hydroxychloroquine-leflunomide (HCQ-LEF) (RepurpSS-I), rituximab (RTX) (TRACTISS) and abatacept3 RCTs
- Participants
- 81 / 24 / 80 / 6
- Comparison
- Response to active treatment vs placebo across 4 transcriptomic endotypes (clusters 1 to 4)
- Cluster 1n = 81
- Cluster 2n = 24
- Cluster 3n = 80
- Cluster 4n = 6
- Primary endpoint
- Therapeutic response by the Sjögren Tool for Assessing Response index, compared across clusters
Methodological detailspooled and individual trial analyses, whole-blood RNA sequencing, semisupervised UMAP with support vector machine model
- Pooled and individual trial analyses
- Whole-blood RNA sequencing
- Semisupervised UMAP with support vector machine model
Primary result
As reported in the abstract
Response rate, active treatment vs placebo, by cluster (pooled)
Response rate
61.5% vs 32.6%
P = 0.016
Further findings
| Outcome | P value |
|---|---|
| ESSDAI, clusters 3 and 4 vs clusters 1 and 2Significantly higher in clusters 3 and 4 | P = 0.003 |
ESSPRI scores across clusters
- Comparable across clusters
Original publication
Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren’s disease. Ann Rheum Dis. Published 24 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →